<table border="single" id="id_067b8260-210f-49f8-8fd2-25ffbb235537" width="533.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_ab3e7b2c-735c-4eb3-aa87-1072349ce9de">Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col width="31.9%"></col>
<col width="24.8%"></col>
<col width="43.3%"></col>
<tbody>
<tr id="id_7aaf63ce-fa2f-4c9c-89dd-e2aa597037da">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="bottom">Concomitant Drug </td>
<td align="center" stylecode="Botrule Rrule" valign="bottom">Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="bottom">Clinical Comment</td>
</tr>
<tr id="id_492d4606-0e2c-451f-b2c6-29d2b151fd21">
<td align="left" stylecode="Lrule Rrule" valign="top">Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Rrule" valign="top">Decreased lamotrigine levels approximately 50%.</td>
</tr>
<tr id="id_fa1ebf40-ced1-4dd8-93fb-86f3232b04e6">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr id="id_12aa5249-41f9-49b9-a463-71e1c8528871">
<td align="left" stylecode="Lrule Rrule" valign="top">Carbamazepine (CBZ) and CBZ epoxide</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Rrule" valign="top">Addition of carbamazepine decreases lamotrigine concentration approximately 40%.</td>
</tr>
<tr id="id_3d945d86-75f3-42ad-88d7-f6f8a18f68ee">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top">? CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May increase CBZ epoxide levels </td>
</tr>
<tr id="id_39a3c026-9cca-404f-be4d-2a0689cf9479">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenobarbital/Primidone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr id="id_15267377-c847-484d-ac45-7538142d6ecf">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenytoin (PHT)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr id="id_aa51efd7-7f7e-4306-9235-68011cbd7c40">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine AUC approximately 40%.</td>
</tr>
<tr id="id_bb5006ff-8e06-4c9f-b5f9-27cee21e08d6">
<td align="left" stylecode="Lrule Rrule" valign="top">Valproate</td>
<td align="left" stylecode="Rrule" valign="top">↑ lamotrigine</td>
<td align="left" stylecode="Rrule" valign="top">Increased lamotrigine concentrations slightly more than 2-fold.</td>
</tr>
<tr id="id_a57cf36d-f0e4-45f4-bb77-304ecdd67d69">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Rrule" valign="top">? valproate</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients. </td>
</tr>
</tbody>
</table>